Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.

@article{Schffski2002ClinicalPI,
  title={Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.},
  author={Patrick Sch{\"o}ffski and A Herr and J. B. Vermorken and Jan Van den Brande and Jos H. Beijnen and Hilde Rosing and Joseph G. Volk and Arnold Ganser and Sabine Adank and H J Botma and Jantien Wanders},
  journal={European journal of cancer},
  year={2002},
  volume={38 6},
  pages={807-13}
}
A randomised, open label phase II study was performed in patients with advanced colorectal cancer to evaluate the safety, toxicity and antineoplastic activity of the topoisomerase I-inhibitor rubitecan. A cross-over design was chosen to determine the intrapatient variation of the bioavailability and pharmacokinetics of the anticancer agent depending on the timing of food intake in relation to the oral drug administration. Patients with previously untreated metastatic disease received two single… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Similar Papers

Loading similar papers…